RVTYRevvity
Is the price fair?
A demanding price: priced for +12% a year vs +1% a year delivered, at the top of its own P/E range, and rich vs its sector.
Priced for ~12% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 76.0 vs a 30.9 median over 41 quarters (+146% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jul 5, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What RVTY's price assumes
Revvity trades at 76.0× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.
Trailing P/E · Diagnostics & Research median 36.7 · 2.07× the median: the market pays up for this one
- Price / sales
- 6.08
Price / sales · today's price, trailing year to Jul 5, 2026
- Free cash flow yield
- 3.1%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered +54% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jul 5, 2026
- 2.45
- EV / EBITtoday's price, trailing year to Jul 5, 2026
- 55.4
- EV / salestoday's price, trailing year to Jul 5, 2026
- 6.83
- Healthcare median P/E503 names
- 27.9
- Diagnostics & Research median P/E33 names
- 36.7
- Free cash flow, trailing twelve months
- $558M
- Market capitalisation111.6 million shares, counted Aug 6, 2026
- $17.7B
- 3-year revenue growth
- +0.87%
- 3-year free cash flow growth
- +54%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 76.0× today against a 30.9× median |
| 52-week range | $82.26 – $158.73 |
| Today | $158.73 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
The closest names by size in the same industry